As 2025 draws to a close, I want to wish you and your family a Merry Christmas, Happy Hanukkah, and Happy New Year. I'm also writing with a profound sense of gratitude for the progress and momentum that the Eyam Team has built over the last 12 months.
This was the year Eyam shifted into high gear. We went from bold hypotheses to hard proof, from promise to performance, from platform potential to real-world traction.
What began as an audacious vision – to build a delivery system that breaks through the barriers of durability, cold-chain, and manufacturing complexity – has taken measurable shape. Across disciplines, across species, and now across partners and programs, Gemini is delivering and Jennerator is accelerating. Our lean, high-integrity team is executing at a level I believe rivals any team in the world, regardless of size or budget.
I believe this year's milestones reflect that evolution. They're not just technical, but translational for the future Eyam is building: one where access to biologics is no longer constrained by logistics, cost, or outdated assumptions.
Below, you'll find our Top 10 breakthroughs of 2025 that captures the breadth of our partnerships and the global reach of our platform.
—Ryan
Top 10 Milestones of 2025
1. Monoclonal Antibody In Vivo Study Completed
In one of our highest-impact studies to date, our Gates Foundation funded program successfully delivered a monoclonal antibody construct via IV in mice, using our Gemini platform. The result? Sustained antibody expression for over 6 months—a striking confirmation of systemic delivery capability.
This wasn't just a mouse study. It was a global signal that Gemini is no longer a theoretical framework, but a chassis ready to carry therapeutic payloads with persistence and precision. Importantly, it validated Gemini's performance with real-world delivery routes (IV), not just lab-optimized ones (IM), and it unlocked partner confidence in therapeutic applications, including malaria and oncology.
Strategic impact: Supports systemic therapeutic use cases and primes regulatory-grade discussions.
2. Gemini Delivered in Pigs
In 2025, we made the leap from rodent to large-animal model by successfully executing a Gemini delivery study in pigs at the Pirbright Institute in the UK.
Just this last week, we received interim data proving that our technology translates well from small animals into larger, much more complex animals. This was a critical inflection point. It proved construct stability and transfection capacity at scale, in a physiological environment closer to humans. Serum analysis is ongoing, but early data affirms Gemini's resilience and translational potential.
Strategic impact: Derisks scale-up and supports human-sized model deployment.
3. Biodistribution Pilot Completed
Regulators don't just want efficacy, they want to know where your vector goes. In our ongoing grant funded study, Gemini constructs expressing luciferase were administered via both IM and IV routes. The result: detectable signal in target tissues, with clear patterns of biodistribution.
We're now expanding the study and data that will anchor our IND-enabling package.
Strategic impact: Advances regulatory readiness, derisks platform pharmacokinetics, and proves Gemini's ability to target specific tissues and organs – a feat few others have achieved.
4. New Malaria Candidates Nominated
In partnership with Medicines for Malaria Venture we designed and have narrowed down to a group of novel antigens to prevent the spread of malaria. This milestone wasn't just technical, it reflected our ability to fuse AI prediction with empirical screening in record time.
It also represents our first WHO-aligned product effort, also backed by Gates-aligned funding and global health urgency.
Strategic impact: Confirms Eyam's relevance in global health positions Gemini for LMIC deployment, and expands Jennerator's design capabilities.
5. Canada-UK Funded Organoid Model Launched
In a bold pivot from traditional animal testing, Eyam launched an organoid-based model in partnership with Canadian and UK agencies. These 3D human tissue analogs grown from stem cells mimic real organ responses and allow for precise, ethically sound immune interrogation.
In this model, we are testing vaccine constructs derived from Jennerator selections, setting a precedent for replacing many animal models in the future. Eyam is one of the first to advance this novel approach, recently promoted by the Food and Drug Administration.
Strategic impact: Accelerates translational timelines while reducing ethical and regulatory friction.
6. Gemini Platform to be Featured in Top Scientific Magazine
Few moments match the validation of being profiled in a top scientific magazine. In 2025, Eyam's Gemini platform was accepted to be spotlighted for its potential to overcome longstanding barriers in nucleic acid delivery—namely, cold chain, dose durability, and manufacturing cost.
The manuscript will position Eyam as a rising force in platform biotech, alongside more resourced incumbents but differentiated by elegant design, speed, and accessibility.
Strategic impact: Elevates scientific credibility and fuels business development exposure.
7. Eyam Signs First Commercial Agreement
After years of platform building and validation, we closed our first commercial agreement for a Gemini-based biologic. This marks our transition from a research-stage company to a revenue-generating biotech with a product footprint.
The terms remain confidential, but the impact is not: this deal confirms the market's appetite for Gemini-powered delivery, and it opens the door for future asset-specific or platform-wide partnerships.
Strategic impact: Begins commercial revenue cycle and validates product-market fit.
8. Strategic Regulatory Data Package Being Built
From the biodistribution study to large animal studies, Eyam built a portfolio of data in 2025 that meets the bar for regulatory engagement. This year's work forms a cohesive, cross-functional data package supporting early-stage IND planning.
Strategic impact: Strengthens foundation for 2026 regulatory conversations and preclinical filings.
9. Eyam Joins Creative Destruction Lab (CDL)
This year, Eyam was accepted into the highly competitive CDL program, one of the world's leading science-driven accelerators. The mentorship and strategic insights gained here will shape our commercial roadmap, partner engagement, and long-term go-to-market plan.
Strategic impact: Accelerates platform commercialization and investor visibility.
10. Multi-Partner Platform Validation
Beyond individual deals, 2025 confirmed something bigger: Gemini works across verticals. We ran or initiated funded programs in malaria (MMV), veterinary health, chronic disease, oncology, and respiratory viral pathogens with external collaborators or co-funding agencies.
This multi-vertical traction isn't just nice to have, it's core to Eyam's vision: a universal delivery platform, untethered from any one indication, capable of carrying high-potency payloads into the hands of researchers, regulators, and patients.
Strategic impact: Validates Gemini as a horizontal platform ready for licensing, adaptation, and scale.
What's Next for Eyam
2026 will bring new studies, further validated data, and deeper engagement with regulatory agencies and clinical partners. Jennerator will continue its evolution as we apply it to increasingly complex antigens, cell types, and immune contexts.
Most importantly, we'll stay focused on our mission: to democratize access to safe, durable biologics that are designed in days, expressed for months, and accessible to all.
If you're a partner, investor, or scientist interested in collaborating please feel free to reach out. Eyam is ready.
Here's to an extraordinary year and a transformative future.
—The Eyam Team